Takemura Kohji, Yamanaka Taro, Hayashida Michikata, Kizawa Rika, Yamaguchi Takeshi, Tanabe Yuko, Sakaguchi Kazushige, Suyama Koichi, Urakami Shinji, Miura Yuji
Department of Medical Oncology Toranomon Hospital Tokyo Japan.
Department of Urology Toranomon Hospital Tokyo Japan.
IJU Case Rep. 2023 Jan 16;6(2):144-146. doi: 10.1002/iju5.12572. eCollection 2023 Mar.
The peripheral nervous system is one of the target organs of immune-related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known.
A man with renal cell carcinoma who received rechallenging immune checkpoint inhibitor therapy developed unilateral facial palsy and was diagnosed with Bell's palsy. He did not have any severe immune-related adverse events during his previous immune checkpoint inhibitor treatment. Corticosteroid therapy was immediately initiated, and his facial palsy symptoms promptly improved.
Physicians should be aware that Bell's palsy can occur as an immune-related adverse event. Additionally, careful observation is necessary during rechallenge with immune checkpoint inhibitors, even in patients who did not have previous immune-related adverse events.
外周神经系统是免疫相关不良事件的靶器官之一。由免疫检查点抑制剂诱发的周围性面神经麻痹，也称为贝尔麻痹，非常罕见，其临床特征尚不清楚。
一名接受再次免疫检查点抑制剂治疗的肾细胞癌男性出现单侧面神经麻痹，并被诊断为贝尔麻痹。他在之前的免疫检查点抑制剂治疗期间没有发生任何严重的免疫相关不良事件。立即开始使用皮质类固醇治疗，其面神经麻痹症状迅速改善。
医生应意识到贝尔麻痹可能作为免疫相关不良事件发生。此外，即使在既往没有免疫相关不良事件的患者中，再次使用免疫检查点抑制剂时也需要仔细观察。
